Medical ConditionsBleeding & blood: Thrombotic thrombocytopenic purpura
Medical ConditionsBleeding & blood: Thrombotic thrombocytopenic purpura
Thrombotic thrombocytopenic purpura
Overview
Board takeaway: Suspected TTP is a hematologic emergency; defer elective dental care and obtain urgent specialist assessment.
What causes thrombotic thrombocytopenic purpura?
Severe ADAMTS13 deficiency permits abnormal von Willebrand factor-mediated platelet aggregation and microvascular thrombosis. Immune-mediated disease results from inhibitory antibodies; congenital disease results from inherited deficiency. Platelets are consumed even as small-vessel clots injure organs.
How does TTP differ from immune thrombocytopenia?
TTP combines thrombocytopenia with microangiopathic hemolytic anemia and potential neurologic, renal, cardiac, or other organ injury. Schistocytes and hemolysis support the concern. Immune thrombocytopenia is a different platelet-destruction disorder; do not apply its observation or transfusion approach to TTP. The complete historic symptom pentad is not required before escalation.
What oral findings can occur in TTP?
Petechiae, ecchymoses, mucosal hematomas, and gingival or other oral bleeding may occur. These findings are nonspecific. Oral bleeding with marked systemic illness, neurologic changes, or hemolysis warrants urgent medical evaluation rather than a dental-only hemostasis plan.
How should dental treatment be planned for a patient with TTP?
Active or suspected TTP requires hospital hematology care and deferral of elective procedures. After stabilization, confirm remission status, current treatment, blood counts, bleeding history, and procedure-specific coverage with hematology. Use atraumatic technique and local hemostasis. Do not infer safety from one platelet threshold or independently arrange prophylactic platelet transfusion.
How is TTP treated and what is the prognosis?
Immune-mediated TTP is treated urgently with therapeutic plasma exchange and immune-directed treatment; additional agents may be used. Congenital TTP requires ADAMTS13 replacement, through plasma or specialist-selected replacement therapy. Treatment choice differs by mechanism and patient. Untreated disease can rapidly be fatal; timely care greatly improves outcomes, but relapse surveillance remains important.